Sino BiopharmaceuticalSBMFF -4.96%62 Operating Margin % is 24.21% as of Dec. 2025, which is 14% above its 10-year median of 21.25. GuruFocus rates SBMFF with a GF Score™ of 62/100 and a GF Value™ of $0.68 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 945 Biotechnology companies, Sino Biopharmaceutical ranks better than 89.52% on this metric.
Sino Biopharmaceutical (OTCPK:SBMFF) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Sino Biopharmaceutical Operating Margin % Related Terms
Sino Biopharmaceutical Operating Margin % Historical Data
* Premium members only.
The historical data trend for Sino Biopharmaceutical's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SBMFF vs VRTX, REGN, ALNY: Operating Margin % Comparison
For the Biotechnology subindustry, Sino Biopharmaceutical's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sino Biopharmaceutical Operating Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Sino Biopharmaceutical's Operating Margin % falls into.
Sino Biopharmaceutical Operating Margin % Calculation
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Sino Biopharmaceutical's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sino Biopharmaceutical (SBMFF) has a Operating Margin % of 24.21% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Sino Biopharmaceutical and its competitors. This is 14% above median its historical median of 21.25. Over the past decade, Sino Biopharmaceutical's Operating Margin % has ranged from 16.21 to 23.23. According to the industry distribution chart, Sino Biopharmaceutical ranks #99 out of 945 companies in the Biotechnology industry, placing it in the top 10.5%.
Is Sino Biopharmaceutical's Operating Margin % too high?
Sino Biopharmaceutical's current Operating Margin % of 24.21% is 14% above median its 10-year median of 21.25. Over the past 10 years, this metric has ranged from a low of 16.21 to a high of 23.23. Based on the distribution chart, Sino Biopharmaceutical ranks #99 out of 945 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sino Biopharmaceutical has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sino Biopharmaceutical's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sino Biopharmaceutical ranks #99 out of 945 companies for Operating Margin %. This places Sino Biopharmaceutical in the top 11% of its industry — outperforming the majority of peers. Historically, Sino Biopharmaceutical's own Operating Margin % has ranged from 16.21 to 23.23 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Sino Biopharmaceutical and its competitors. Sino Biopharmaceutical's current Operating Margin % is 24.21%, which is 14% above median its own 10-year median of 21.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sino Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Sino Biopharmaceutical (SBMFF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.68, compared to a current price of $0.60 — trading 11.5% below its estimated fair value. The current Operating Margin % is 24.21%, which is 14% above median its 10-year median of 21.25. Sino Biopharmaceutical's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Sino Biopharmaceutical (SBMFF), the current Operating Margin % is 24.21% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sino Biopharmaceutical (SBMFF) Overvalued in 2026?
Based on GuruFocus' analysis, Sino Biopharmaceutical stock appears to be undervalued.
The current stock price of $0.60 is trading 11.5% below its estimated GF Value™ of $0.68.
GuruFocus considers Sino Biopharmaceutical to be Modestly Undervalued.
Key valuation signals for SBMFF:
Operating Margin %: 24.21% (14% above median its 10-year median of 21.25)
GF Value™: $0.68 vs. price of $0.60 (11.5% below fair value)
No single metric tells the full story. See the SBMFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sino Biopharmaceutical Ltd is an investment holding company. The company and its subsidiaries are principally engaged in the research and development, production and sale of a series of pharmaceutical products. Its business covering the entire industrial chain of R&D, production and commercialization of drugs, biological products and high-end generic drugs. The company's therapeutic areas include: oncology, liver disease, respiratory, and surgery/pain relief. The company's revenue was generated from the sale of pharmaceutical products in the Chinese mainland.
62GF Score
Get the complete analysis for SBMFF
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBMFF has been successfully added to your 
